MA50159A - Nouvelles combinaisons stables de charpentes de domaines variables d'anticorps - Google Patents

Nouvelles combinaisons stables de charpentes de domaines variables d'anticorps

Info

Publication number
MA50159A
MA50159A MA050159A MA50159A MA50159A MA 50159 A MA50159 A MA 50159A MA 050159 A MA050159 A MA 050159A MA 50159 A MA50159 A MA 50159A MA 50159 A MA50159 A MA 50159A
Authority
MA
Morocco
Prior art keywords
antibodies
frames
new stable
variable areas
stable combinations
Prior art date
Application number
MA050159A
Other languages
English (en)
Inventor
Dania Diem
Christian Hess
Sebastian Meyer
David Urech
Original Assignee
Numab Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Numab Therapeutics AG filed Critical Numab Therapeutics AG
Publication of MA50159A publication Critical patent/MA50159A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA050159A 2017-09-20 2018-09-19 Nouvelles combinaisons stables de charpentes de domaines variables d'anticorps MA50159A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17192206.5A EP3459968A1 (fr) 2017-09-20 2017-09-20 Nouvelles combinaisons de structure de domaines variables d'anticorps stables

Publications (1)

Publication Number Publication Date
MA50159A true MA50159A (fr) 2020-07-29

Family

ID=59982265

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050159A MA50159A (fr) 2017-09-20 2018-09-19 Nouvelles combinaisons stables de charpentes de domaines variables d'anticorps

Country Status (8)

Country Link
US (2) US11421035B2 (fr)
EP (2) EP3459968A1 (fr)
JP (2) JP2020535799A (fr)
CN (1) CN111133000A (fr)
AU (1) AU2018335823B2 (fr)
CA (1) CA3073882A1 (fr)
MA (1) MA50159A (fr)
WO (1) WO2019057787A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1218549A1 (zh) * 2013-06-26 2017-02-24 Numab Therapeutics AG 新型抗体框架
EP3816185A1 (fr) 2019-11-04 2021-05-05 Numab Therapeutics AG Anticorps multi-spécifique contra pd-l1 et antigène associé à une tumeur
EP3915580A1 (fr) 2020-05-29 2021-12-01 Numab Therapeutics AG Anticorps multi-spécifique
EP3988568A1 (fr) 2020-10-21 2022-04-27 Numab Therapeutics AG Traitement combiné
EP4019546A1 (fr) 2020-12-23 2022-06-29 Numab Therapeutics AG Domaines variables d'anticorps qui se lient à il-31
EP4019090A1 (fr) 2020-12-23 2022-06-29 Numab Therapeutics AG Domaines variables d'anticorps liant il-4r
WO2022136693A1 (fr) 2020-12-23 2022-06-30 Numab Therapeutics AG Domaines variables d'anticorps et anticorps ayant une immunogénicité réduite
EP4019547A1 (fr) 2020-12-23 2022-06-29 Numab Therapeutics AG Anticorps multispécifiques ayant une spécificité pour il-4r et il-31
EP4267614A1 (fr) 2020-12-23 2023-11-01 Numab Therapeutics AG Domaines variables d'anticorps se liant à il-31
JP7858665B2 (ja) 2021-02-02 2026-05-14 ヌマブ セラピューティックス アーゲー Ror1およびcd3に対する特異性を有する多重特異性抗体
US20220259296A1 (en) 2021-02-12 2022-08-18 Boehringer Ingelheim International Gmbh Complement c3 antigen binding proteins
EP4183800A1 (fr) 2021-11-19 2023-05-24 Medizinische Hochschule Hannover Nouveaux anticorps neutralisants du sars-cov-2
PE20250390A1 (es) 2021-12-22 2025-02-11 Boehringer Ingelheim Int Anticuerpos anti-c3 y fragmentos de union al antigeno de estos y sus usos para tratar enfermedades oftalmicas u oculares
EP4273162A1 (fr) 2022-05-06 2023-11-08 Numab Therapeutics AG Domaines variables d'anticorps et anticorps présentant une immunogénicité réduite
CN119487062A (zh) 2022-05-06 2025-02-18 努玛治疗有限公司 具有降低的免疫原性的抗体可变结构域和抗体
WO2024038095A1 (fr) 2022-08-16 2024-02-22 Iome Bio Nouveaux anticorps anti-rgmb
PE20260551A1 (es) 2023-05-19 2026-03-04 Numab Therapeutics AG Dominios variables de anticuerpos y anticuerpos con inmunogenicidad disminuida
IL328540A (en) 2023-12-22 2026-07-01 Numab Therapeutics AG Antibody binding complexes specific for LILRB2

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP0859841B1 (fr) * 1995-08-18 2002-06-19 MorphoSys AG Banques de proteines/(poly)peptides
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ,インコーポレイティド 人工抗体ポリペプチド
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
CN100415765C (zh) 2003-08-07 2008-09-03 宜康公司 兔单克隆抗体的人源化方法
SI3219328T1 (sl) * 2005-12-29 2020-10-30 Janssen Biotech, Inc. Človeška protitelesa proti-IL-23, sestavki, postopki in uporabe
WO2008004834A1 (fr) 2006-07-06 2008-01-10 Isu Abxis Co., Ltd Anticorps monoclonal humanisé à forte liaison au récepteur de facteur de croissance épidermique, récepteur egf
NZ601583A (en) 2007-05-21 2013-08-30 Bristol Myers Squibb Co Novel rabbit antibody humanization methods and humanized rabbit antibodies
PL2307458T3 (pl) 2008-06-25 2018-08-31 Esbatech, An Alcon Biomedical Research Unit Llc Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała
US8193235B2 (en) 2009-06-12 2012-06-05 University Of Kansas Compositions and methods for establishing and maintaining stem cells in an undifferentiated state
CN113234142B (zh) * 2012-08-22 2024-03-05 财团法人牧岩生命工学研究所 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用
HK1218549A1 (zh) 2013-06-26 2017-02-24 Numab Therapeutics AG 新型抗体框架
WO2015058861A1 (fr) * 2013-10-25 2015-04-30 Numab Ag Constructions bispécifiques et leur utilisation dans le traitement de diverses maladies
KR20250091329A (ko) 2015-06-15 2025-06-20 누맙 세러퓨틱스 아게 이종 이량체 다중 특이적 항체 포맷

Also Published As

Publication number Publication date
US20230242651A1 (en) 2023-08-03
EP3459968A1 (fr) 2019-03-27
JP2020535799A (ja) 2020-12-10
AU2018335823B2 (en) 2025-09-04
US11421035B2 (en) 2022-08-23
US20200255533A1 (en) 2020-08-13
JP2023115024A (ja) 2023-08-18
CN111133000A (zh) 2020-05-08
WO2019057787A1 (fr) 2019-03-28
AU2018335823A1 (en) 2020-02-27
CA3073882A1 (fr) 2019-03-28
EP3684802A1 (fr) 2020-07-29

Similar Documents

Publication Publication Date Title
MA49043A (fr) Formulation stable d'anticorps
EP3768854A4 (fr) Modulation de l'expression de hsd17b13
EP3784707A4 (fr) Compositions de microcapsules de polyurée stables
MA49726A (fr) Formulation d'anticorps anti-cgrp
EP3618871A4 (fr) Formulations d'anticorps anti-lag3 etco-formulations d'anticorps anti-lag3 et d'anticorps anti-pd-1
EP3478249A4 (fr) Compositions de microcapsules stables
MA46820A (fr) Composition pharmaceutique comprenant des constructions d'anticorps bi-spécifiques
MA47494A (fr) Nouvelles utilisations d'anticorps anti-sirpg
MA42924A (fr) Variants optimisés d'anticorps anti-vegf
EP3615079C0 (fr) Formulations de cannabinoïdes stables
EP3518971A4 (fr) Formulations thérapeutiques d'anticorps et de protéines et leurs utilisations
EP3601569A4 (fr) Modulateurs de l'expression de pcsk9
EP3823978A4 (fr) Compositions d'anticorps anti-fcrn
MA54052A (fr) Formulation d'anticorps
EP3481814A4 (fr) Antagonistes de l'intégrine tetrahydronaphthyridinepentanamide
EP3328429A4 (fr) Peptides et anticorps pour l'élimination de biofilms
EP3938077A4 (fr) Analyseur de concentration de point d'intervention
EP3893931A4 (fr) Méthodes d'utilisation d'anticorps anti-trem2
EP3773721A4 (fr) Formulations d'immunoconjugué anti-cd79b stables
EP3692072A4 (fr) Anticorps anti-hla-dq2.5
MA54139A (fr) Formulation d'anticorps
MA43361A (fr) Composition pour le soin et la protection de cultures
MA53466A (fr) Formulation stable d'anticorps anti-osmr
FR3022462B1 (fr) Composition orale d'anticorps anti-tnfalpha
IL263997A (en) Human-enzyme mediated depletion of cystine